BR101 in Patients With Relapsed/Refractory Multiple Myeloma
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting · NCT07537049 · Registry updated 2026-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BR101 in Patients With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 | 2026-04-17 | NCT07537049 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Byterna Therapeutics Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing | China | 16 |